In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Galenica Pharmaceuticals Inc.

Latest From Galenica Pharmaceuticals Inc.

Scrip 100: The Architecture Of A Top Heavy Industry

Pharmaceutical revenues were down slightly; so was R&D spending, thanks to a strengthening dollar. Scrip analyzes 620 companies and uses numbers, clocks and tiers to paint some data pictures of the pharmaceutical industry in 2015.

Commercial Market Intelligence

2016 Pharma Dealmaking: Waiting On The High-Value Deals

Six pharma deals announced thus far in 2016 carried up-front values of $1 billion or more, down considerably from the high-volume, high-value M&A industry experienced the prior two years. Pharma manufacturers appear to be recalibrating – digesting previous acquisitions, adjusting to new biotech valuations and taking stock of the political and macro-economic climate – but fundamentals suggest pharma dealmaking will pick up. Pfizer’s $14 billion offer for Medivation might represent a turning point.

BioPharmaceutical Deals

Amgen Q2 Sales Rise, But Growth Depends On Repatha And Beyond

Execs faced questions about commercial preparations and potential label for Amgen’s PCSK9 inhibitor, we well as speculation about what the appointment of former Schering CEO Fred Hassan to the board means for Amgen’s M&A strategy.

BioPharmaceutical Business Strategies

Will Velphoro’s Convenience Advantage Be Enough In Crowded ESRD Field?

With the field going generic and a new brand competitor with additional advantages on the way, Vifor Pharma is counting on lower pill burden to propel hyperphosphatemia drug Velphoro.

BioPharmaceutical North America
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines